Increased tropospheric ozone levels enhance pathogen infection levels of amphibians

As a result of anthropogenic activities, changes to the chemistry of Earth's atmosphere pose a threat to ecosystem health and biodiversity. One such change is the increase in tropospheric ozone (O3), which is particularly severe in the Mediterranean basin area, where the levels of this pollutant are chronically high during spring and summer time. Within this region, Mediterranean mountain ecosystems are hot spots for biodiversity which may be especially vulnerable to changes in O3 levels. Declines in montane amphibian populations have been recorded worldwide, including the Mediterranean basin. A significant driver of these declines is the emerging infection disease, chytridiomycosis, caused by the aquatic fungus Batrachochytrium dendrobatidis (Bd). Chytridiomycosis has negatively affected populations of several amphibian species in the Spanish Central Range, including in the Sierra Guadarrama, and interactions with other biotic and abiotic factors are an important part of these declines. However, there is little evidence or knowledge of whether tropospheric O3 levels may be another factor in the outbreaks of this disease. To test the hypothesis that O3 levels are another interactive driver of Bd infection dynamics, two different approaches were followed: 1) an experimental study in open top chambers was used to quantify the aspects of how Bd infection progressed throughout the metamorphic process under four different O3 levels; and 2) a field epidemiological study was used to analyse the relationship between the Bd infection load in the Sierra de Guadarrama and tropospheric O3 levels during a 9 year period. Our results suggest that high O3 levels significantly delayed the rate of development of tadpoles and increased Bd infection, providing empirical evidence of two new separate ways that may explain population declines of montane amphibians

Desarrollo de tecnologías para evaluar la funcionalidad de pacientes con prótesis de rodilla y su uso para el seguimiento clínico post-comercialización de productos sanitarios y la estimación de indicadores de gestión hospitalaria

Gomez Pellin, A.; Pedrero, J.; Peris Serra, JL.; Sinovas, I.; Atienza Vicente, CM.; Garrido Jaen, JD.; Bermejo Bosch, I.... (2019). Desarrollo de tecnologías para evaluar la funcionalidad de pacientes con prótesis de rodilla y su uso para el seguimiento clínico post-comercialización de productos sanitarios y la estimación de indicadores de gestión hospitalaria. Innovación biomecánica en Europa. (8):1-4. http://hdl.handle.net/10251/167980S14

Cognitive impairment in patients with Fibromyalgia syndrome as assessed by the Mini-Mental State Examination

<p>Abstract</p> <p>Background</p> <p>This study evaluated the frequency of cognitive impairment in patients with Fibromyalgia syndrome (FMS) using the Mini Mental State Examination (MMSE).</p> <p>Methods</p> <p>We analyzed baseline data from all 46 patients with FMS and 92 age- and sex-matched controls per diagnosis of neuropathic (NeP) or mixed pain (MP) selected from a larger prospective study.</p> <p>Results</p> <p>FMS had a slight but statistically significant lower score in the adjusted MMSE score (26.9; 95% CI 26.7-27.1) than either NeP (27.3; 95% CI 27.2-27.4) or MP (27.3; 27.2-27.5). The percentage of patients with congnitive impairment (adjusted MMSE ≤ 26) was numerically higher in FMS (15%; 95% CI 6.3-29) compared with NeP (5%; 95% CI 1.8-12.2) or MP (5%; 95% CI 1.8-12.2) and higher than in the same age stratum of the general population (0.05%).</p> <p>Conclusions</p> <p>Compared with the population reference value, patients with FMS showed high frequency of cognitive impairment.</p

Effects of maternal modafinil treatment on fetal development and neonatal growth parameters — a multicenter case series of the European Network of Teratology Information Services (ENITS)

\ua9 2023 The Authors. Acta Psychiatrica Scandinavica published by John Wiley &amp; Sons Ltd.Objective: In recent years, safety concerns about modafinil exposure during pregnancy have emerged. In particular, increased risks for major congenital anomalies (MCA) and impaired fetal growth were reported, although study results were conflicting. Our investigation aims to examine previously reported safety signals. Method: Multicenter case series based on data from 18 Teratology Information Services from 12 countries. Modafinil exposed pregnancies with an estimated date of birth before August 2019 were included in this study. For prospectively ascertained pregnancies, cumulative incidences of pregnancy outcomes, rate of nonchromosomal MCA in first trimester exposed pregnancies and percentiles of neonatal/infant weight and head circumference (HC) were calculated. Potential dose-dependent effects on fetal growth were explored by linear regression models. Retrospectively ascertained cases were screened for pattern of MCA and other adverse events. Results: One hundred and seventy-five prospectively ascertained cases were included, of which 173 were exposed at least during the first trimester. Cumulative incidences for live birth, spontaneous abortion and elective termination of pregnancy were 76.9% (95% CI, 68.0%–84.8%), 9.3% (95% CI, 5.0%–16.9%), and 13.9% (95% CI, 8.1%–23.1%), respectively. Nonchromosomal MCA was present in 3/150 live births, corresponding to an MCA rate of 2.0% (95%CI, 0.6%–6.1%), none were reported in pregnancy losses. Compared to reference standards, birth weight (BW) tended to be lower and neonatal HC to be smaller in exposed newborns (data available for 144 and 73 of 153 live births, respectively). In nonadjusted linear regression models, each 100 mg increase of average dosage per pregnancy day was associated with a decrease in standard deviation score (SDS) of −0.28 SDS (95% CI, −0.45 to −0.10) for BW and of −0.28 SDS (95% CI, −0.56 to 0.01) for HC. Screening of 22 retrospectively reported cases did not reveal any specific pattern of MCA or other adverse outcomes. Conclusion: The results do not indicate an increased risk of MCA after in utero exposure to modafinil, but a tendency toward lower BW and reduced neonatal HC. However, these findings should be regarded as preliminary. Until further studies allow for a definite conclusion, modafinil should not be used during pregnancy

Effects of maternal modafinil treatment on fetal development and neonatal growth parameters - a multicenter case series of the European Network of Teratology Information Services (ENTIS).

In recent years, safety concerns about modafinil exposure during pregnancy have emerged. In particular, increased risks for major congenital anomalies (MCA) and impaired fetal growth were reported, although study results were conflicting. Our investigation aims to examine previously reported safety signals. Multicenter case series based on data from 18 Teratology Information Services from 12 countries. Modafinil exposed pregnancies with an estimated date of birth before August 2019 were included in this study. For prospectively ascertained pregnancies, cumulative incidences of pregnancy outcomes, rate of nonchromosomal MCA in first trimester exposed pregnancies and percentiles of neonatal/infant weight and head circumference (HC) were calculated. Potential dose-dependent effects on fetal growth were explored by linear regression models. Retrospectively ascertained cases were screened for pattern of MCA and other adverse events. One hundred and seventy-five prospectively ascertained cases were included, of which 173 were exposed at least during the first trimester. Cumulative incidences for live birth, spontaneous abortion and elective termination of pregnancy were 76.9% (95% CI, 68.0%-84.8%), 9.3% (95% CI, 5.0%-16.9%), and 13.9% (95% CI, 8.1%-23.1%), respectively. Nonchromosomal MCA was present in 3/150 live births, corresponding to an MCA rate of 2.0% (95%CI, 0.6%-6.1%), none were reported in pregnancy losses. Compared to reference standards, birth weight (BW) tended to be lower and neonatal HC to be smaller in exposed newborns (data available for 144 and 73 of 153 live births, respectively). In nonadjusted linear regression models, each 100 mg increase of average dosage per pregnancy day was associated with a decrease in standard deviation score (SDS) of -0.28 SDS (95% CI, -0.45 to -0.10) for BW and of -0.28 SDS (95% CI, -0.56 to 0.01) for HC. Screening of 22 retrospectively reported cases did not reveal any specific pattern of MCA or other adverse outcomes. The results do not indicate an increased risk of MCA after in utero exposure to modafinil, but a tendency toward lower BW and reduced neonatal HC. However, these findings should be regarded as preliminary. Until further studies allow for a definite conclusion, modafinil should not be used during pregnancy

Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100, 000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery. © 2021 by the authors. Licensee MDPI, Basel, Switzerland

El Empoderamiento en el ámbito de la gerontología clínica y social = Empowerment in social and clinical gerontology context

El empoderamiento en el ámbito de la gerontología clínica y socia

FallSkip: Valoración del riesgo de caídas en personas mayores

[ES] Una realidad evidente a día de hoy es el envejecimiento de la población mundial. El aumento de la población mayor de 65 años implica un incremento en el número de caídas. Según la OMS, las estrategias de prevención a adoptar por los sistemas de salud deben dirigirse a la identificación de los factores de riesgo. En este sentido, el Instituto de Biomecánica (IBV), dentro de su línea de investigación en personas mayores, ha definido un protocolo clínico a partir de una modificación del test Time up & Go (TUG) con el fin de obtener un índice del riesgo de caída sencillo y fiable. Este índice se elabora a partir de registros biomecánicos que han permitido definir un modelo de clasificación del riesgo de caída. Este modelo se basa en el patrón de marcha, equilibrio, potencia muscular, así como en variables temporales. Finalmente se han desarrollado nuevas soluciones tecnológicas para su aplicación tanto a nivel de asistencia primaria como especializada.Medina Ripoll, E.; Pedrero Sánchez, JF.; Garrido Jaen, JD.; Lopez Pascual, J.; Bermejo Bosch, I.; Pitarch Corresa, S.; Sinovas Alonso, I.... (2017). FallSkip: Valoración del riesgo de caídas en personas mayores. Revista de Biomecánica (Online). (64). http://hdl.handle.net/10251/104205S6